News

Protagen AG join forces with the U.S. National Cancer Institute to answer pressing questions in immuno-oncology

Protagen AG has executed a Material Transfer Agreement with the National Cancer Institute (NCI) under which the parties will utilize Protagens SeroTag® immune system profiling technology to identify biomarkers that predict therapy responsiveness, to monitor patients receiving immunotherapies, and for early detection of immune-related adverse events (irAEs). This collaboration with NCI will be led by Jeffrey Schlom, Ph.D., Chief of the Laboratory of Tumor Immunology and Biology at the NCI’s Center for Cancer Research.

The German National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG Investigate Responsiveness to Checkpoint Inhibitors in Melanoma

The German National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG today announced a collaboration to utilize Protagen’s SeroTag® technology to identify biomarkers that predict therapy responsiveness and the detection of immune-related adverse events (irAEs) in melanoma patients treated with checkpoint inhibitors.

Protagen AG successfully joined forces with Novartis to support Clinical Development of a Novel Compound in an Autoimmune Indication

PROTAGEN AG, a leading provider of pharma development services, novel diagnostic tests and companion diagnostics in the fields of immuno-oncology and autoimmune disease, today announced the successful completion a collaboration agreement with Novartis Pharma AG. During the collaboration, Protagen utilized its proprietary SeroTag technology to discover prediction as well as patient stratification markers for a novel drug being developed by Novartis.

PROTAGEN Launches NavigAID Assay to Support Clinical Drug Development for Autoimmune Diseases

Systemic Sclerosis (SSc) Disease Stratification Assay expands the NavigAID product line across multiple potential targeted therapies and disease states

Protagen AG, a leading provider of pharma development services, companion diagnostics and novel diagnostic tests in the fields of immuno-oncology and autoimmune disease, today announced the launch of NavigAID SSc, a disease stratification assay designed to support pharmaceutical and biotechnology companies with their Systemic Sclerosis (SSc) drug development efforts.

Protagen AG Announces Changes to Their Management Board

Protagen AG. a leading provider of pharma development services, novel diagnostic tests and companion diagnostics in the fields of immuno-oncology and autoimmune disease, today announced changes to their Management Board. Dr. Georg Lautscham will join the company's Management Board and Dr. Stefan Müllner will resign from his position as CEO.

This announcement follows recent changes to the company's Supervisory Board of Directors, and accelerates the company’s evolution from development stage, into a successful commercial business.

Protagen Inks License Agreement with Inova Diagnostics for its proprietary BICD2 Biomarker

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics in the autoimmune field, and Inova Diagnostics, a global leader in the development and commercialization of in-vitro diagnostic systems and reagents for autoimmune diseases, have signed a semi-exclusive license agreement for BICD2, a novel autoantigen and the first proprietary biomarker discovered by Protagen employing its SeroTag® technology.

Protagen AG Appoints Bernhard Kirschbaum as New Chairman and Oliver Schacht as New Board Member

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics (CDx) in the autoimmune field, today announced that Dr. Oliver Schacht, CEO of Curetis N.V., Holzgerlingen, has joined the company's Supervisory Board. Additionally, Dr. Bernhard Kirschbaum, former Merck Pharma Executive and member of the Protagen Board since 2015, was elected as the new Chairman, taking over the position from Prof. Dr. Axel Kleemann.

Protagen announces CE Mark for its proprietary Multilisa® BICD2 test for better diagnosis of Systemic Sclerosis

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics in the autoimmune field, today announced that it gained CE marking for the Multilisa® BICD2 test. BICD2 is the first proprietary biomarker discovered by Protagen employing the SeroTag® technology platform, and provides significant added value to standard diagnostics for Systemic Sclerosis (SSc).

Protagen launches first CE marked diagnostic assays Multilisa CENP-B and Scl-70 for the diagnosis of Systemic Sclerosis

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics in the autoimmune field, today announced the launch of its first CE marked diagnostic assays Multilisa® CENP-B and Multilisa® Scl-70 ELISA to aid in the diagnosis of Systemic Sclerosis (SSc).

Protagen AG have been nominated as one of three finalists in the 'Best Personalized Medicine Advance or Application' category of the prestigious Clinical and Research Excellence (CARE) awards

Protagen AG have been nominated based on the NavigAID Systemic Lupus Erythematosus (SLE) array that was developed using the proprietary Protagen SeroTag® technology.

NavigAID SLE measures autoantibodies associated specifically with SLE and also identifies subsets of autoantibodies associated with particular SLE disease states and pathologies. This is the first time it has been possible to differentiate between different SLE patient subgroups and currently this technology is being applied to the development of an SLE companion diagnostic with a global pharmaceutical partner.

Novel route to serum based Prostate Cancer Diagnostics

Protagen AG, technology leader in the development of novel molecular diagnostic and companion diagnostic tests for autoimmune diseases and oncological indications, announced today the identification of novel protein biomarkers in prostate cancer, which are potential drug targets supporting novel strategies in precision medicine.

Protagen AG joins RA-MAP Consortium to support Identification of Predictors of Remission in Rheumatoid Arthritis (RA)

Protagen AG, a company concerned with the development of advanced diagnostic tools to address some of the most severe autoimmune diseases, has today announced that it will join the RA-MAP Consortium. The overarching goal of the Consortium is to identify the key predictors of clinical response and remission in RA patients, and to identify those individuals at high risk of developing Rheumatoid Arthritis (RA).

Protagen AG establishes Scientific Advisory Board

Protagen AG, technology leader in the development of novel molecular diagnostics and companion diagnostic concepts for autoimmune diseases, announced today the formation of its Scientific Advisory Board (SAB). The SAB is comprised of two experienced and renowned clinical rheumatology experts; Professor Vibeke Strand, Stanford University, and Professor Matthias Schneider, Duesseldorf University.

Protagen AG joins MATURA Consortium to support Identification of Treatment Response Predictors in Rheumatoid Arthritis (RA)

Protagen AG, a company concerned with the development of advanced diagnostic tools to address some of the most severe autoimmune diseases, has today announced that it will join the MATURA Consortium. The overarching mission of the MATURA Consortium is to improve patient care in Rheumatoid Arthritis (RA) by rationalizing therapy decisions through a stratified medicine approach.

Protagen launches Multilisa BICD2 offering new options in diagnosing Systemic Sclerosis (SSc)

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics in the autoimmune field, today launched Multilisa® BICD2 a research use only (RUO) ELISA to aid in the diagnosis of Systemic Sclerosis (SSc).

Protagen and Mikrogen agree on Co-development of Novel Lyme Disease Markers

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics in the autoimmune field, and Mikrogen GmbH, the European market leader in Lyme disease diagnostics, agreed on a co-development program for a new diagnostic assay to distinguish between previously infected, seropositive individuals, from newly infected patients with active Lyme disease.

The agreement builds on a previous research collaboration between both companies and the results obtained using the proprietary SeroTag® technology developed by Protagen.

Protagen AG Appoints New Board Members to Expand Expertise in Diagnostics Commercialization

Protagen AG, the technology leader in the development of novel molecular diagnostic and companion diagnostic tests for autoimmune diseases, has elected Dr. Dirk Ehlers, CEO of Trumpf Medical in Puchheim, to the company's Supervisory Board.

Simultaneously, Wolfgang Kintzel, Senior Investment Manager of NRW.BANK in Düsseldorf, succeeded Dr. Aristotelis Nastos as representative of NRW.BANK, and Matthias Guth, was appointed by MIG AG in Munich, to follow Michael Motschmann in his board position.

Protagen AG Achieves Significant Milestone with ISO 13485 Certification

PROTAGEN AG, a company concerned with the development of advanced diagnostic tools to address some of the most severe autoimmune diseases, has received the ISO 13485 certification, and now officially complies with the internationally recognized quality standard for medical devices.

NavigAID SLE - Protagen zooms into the micro cosmos of Autoimmune Disease

PROTAGEN AG, a company dedicated to the development of powerful diagnostic tools to address some of the most severe autoimmune diseases, has today launched NavigAID SLE, a patient stratification array, to support Pharma and Biotech companies with their Systemic Lupus Erythematosus (SLE) drug development efforts.

Protagen AG Appoints Bernhard Kirschbaum as New Board Member

PROTAGEN AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics (CDx) in the autoimmune field, today announced that the former Head of Research and Early Development of Merck-Serono, Dr. Bernhard Kirschbaum, has joined the company’s Supervisory Board.

Protagen Successfully Closes New Financing Round

PROTAGEN AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics in the autoimmune field, today announced the closing of a new financing round. In this round, QIAGEN N.V., joins existing investors MIG Fonds, Munich, NRW.BANK, Düsseldorf, and Protagen Management.

This is the first closing of a financing round with a total volume of € 10 Mio. The second closing with additional new investors is planned for the third quarter of 2015.

Protagen AG signs collaboration with QIAGEN to develop novel protein based companion Diagnostics for autoimmune therapies

Protagen and QIAGEN partner to offer pharmaceutical companies an innovative companion diagnostic development platform for autoimmune disorders.

Collaboration with QIAGEN to accelerate market acceptance for SeroTag.

Protagen AG Launches Landmark First Research Test Kit for Systemic Sclerosis

Protagen AG, a company dedicated to the development of powerful diagnostic tools to address some of the most severe autoimmune diseases, has today launched its first ELISA research use test kit for Systemic Sclerosis (SSc), the ADx SSc Multilisa®. Protagen developed the new assay to synergistically combine two proprietary, novel disease markers with two standard diagnostic markers to support medical research in autoimmune diseases.

Protagen Selected by Pfizer to Support Clinical Drug Development of a Novel Compound in Autoimmune Diseases

Protagen announced today that a collaboration agreement with Pfizer Inc. has been signed. Under the collaboration, Protagen will use its proprietary SeroTag process to attempt to discover prediction or patient stratification markers for a novel drug being developed by Pfizer.